Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 3

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 3
---
 and/or its subsidiaries, with the exception of:

• trademarks used or that may be or have been used under license by Sanofi and/or its affiliates, such as Aldurazyme, a

trademark of the Biomarin/Genzyme LLC Joint Venture; Alprolix, a trademark of Swedish Orphan Biovitrum AB in Europe;

ALTUVIIIO , a trademark of Sobi in Europe and in Africa; Anket, a trademark of Innate Pharma; Atomnet, a trademark of

Atomwise, Inc.; Cialis, a trademark of Eli Lilly; Eloctate, a trademark of Swedish Orphan Biovitrum AB in Europe; Stamaril, a

trademark of the Institut Pasteur; Tamiflu, a trademark of Hoffmann-La Roche; Vaxelis, a trademark of MSP Vaccine Company

(US) and MCM Vaccine B.V. (Netherlands); Zaltrap, a trademark of Regeneron in the United States;

• trademarks sold by Sanofi and/or its affiliates to a third party, such as Altace, a trademark of King Pharmaceuticals in the

United States; Libtayo, a trademark of Regeneron; Praluent, a trademark of Regeneron in the United States; and

• other third party trademarks such as Stoxx, a trademark of Stoxx Ltd; and Zantac, a trademark of Glaxo Group Limited (except

in the US and Canada).

Not all trademarks related to products under development have been authorized as of the date of this annual report by the

relevant health authorities.

The data relating to market shares and ranking information for medicines and vaccines, in particular as presented

in “Item 4. Information on the Company — B. Business Overview — B.5. Markets — B.5.1. Marketing and distribution,” are based

primarily on sales data excluding vaccines and in constant euros (unless otherwise indicated) on a September 2024 moving

annual total (MAT) basis. The data are primarily from a IQVIA local sales audit, supplemented by country-specific sources.

Product indications described in this annual report are composite summaries of the major indications approved in the product’s

principal markets. Not all indications are necessarily available in each of the markets in which the products are approved. The

summaries presented herein for the purpose of financial reporting do not substitute for careful consideration of the full labeling

approved in each market.

Cautionary statement regarding

forward-looking statements

This annual report